A pharmaceutical company raises the price of the EpiPen from $100 to more than $600, and increases its CEO’s salary from $5 million to $19 million. An insurance company withdraws from the Affordable Care Act exchanges with the claim that it is losing money, as opposed to admitting it was fulfilling a threat because its merger didn’t get approved. A recent report debunks the lie that drug prices are high by necessity, in order to promote the development of new medicines.